List view / Grid view
Prof. Klaus Dugi serves as Corporate Senior Vice President of Medicine and Chief Medical Officer at Boehringer Ingelheim GmbH.
The application for European marketing authorisation of faldaprevir* has been…
26 November 2013 | By Boehringer Ingelheim
The application for European marketing authorisation of faldaprevir* has been fully validated and granted accelerated assessment by the European Medicines Agency...
Pradaxa® is the only novel oral anticoagulant with more than…
19 November 2013 | By Boehringer Ingelheim
Pradaxa® is the only novel oral anticoagulant with more than 6 years of long-term data supporting its beneficial role for stroke prevention...
"Our extensive studies have demonstrated that tiotropium Respimat® has the…
13 November 2013 | By Boehringer Ingelheim
"Our extensive studies have demonstrated that tiotropium Respimat® has the potential to be an effective new treatment..."
Boehringer Ingelheim announces clinical experience with its angiotensin II receptor…
11 November 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces clinical experience with its angiotensin II receptor blocker (ARB) has reached 50 million patient-years of real world experience...
"These data are encouraging and reinforce the potential benefits of…
2 November 2013 | By Boehringer Ingelheim
"These data are encouraging and reinforce the potential benefits of faldaprevir* as an effective treatment..."
“Exercise is an essential component of COPD management..."
29 October 2013 | By Boehringer Ingelheim
“Exercise is an essential component of COPD management..."
"The new sub-analysis confirms the consistent safety profile of afatinib…
27 October 2013 | By Boehringer Ingelheim
"The new sub-analysis confirms the consistent safety profile of afatinib in Asian patients..."
"The improvements in lung function and quality of life seen…
18 October 2013 | By Boehringer Ingelheim
"The improvements in lung function and quality of life seen with once-daily Striverdi® Respimat® are remarkable..."
Nintedanib*, when added to chemotherapy, is the first lung cancer…
14 October 2013 | By Boehringer Ingelheim
Nintedanib*, when added to chemotherapy, is the first lung cancer treatment that extended patient survival...
"These results are promising particularly because they show the potential…
8 October 2013 | By Boehringer Ingelheim
"These results are promising particularly because they show the potential to evaluate harder-to-treat populations..."
Anticoagulants are an indispensable treatment to prevent dangerous blood clots…
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies.3 This research shows that applying existing…
Boehringer Ingelheim and Eli Lilly and Company today announced that…
24 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented…
Boehringer Ingelheim announced the completion of patient enrolment for a…
10 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the completion of patient enrolment for a Phase IIa clinical trial...
Data from two 48 week Phase III studies involving more…
9 September 2013 | By Boehringer Ingelheim
Data from two 48 week Phase III studies involving more than 3,000 patients...
Boehringer Ingelheim announces new plans to expand body of evidence…
3 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces new plans to expand body of evidence for Pradaxa®...
